Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PARADI MIRMIRANI

Allopathic & Osteopathic Physicians Dermatology

NPI
1780758086
CMS profile
528173
Location
VALLEJO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$16,185.62

11 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $14,150.00 4
Travel and Lodging $1,692.01 3
Food and Beverage $343.61 4

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
SUN PHARMACEUTICAL INDUSTRIES INC. $11,535.62 9
PFIZER INC. $3,850.00 1
Eli Lilly and Company $800.00 1

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PARADI MIRMIRANI

NPI 1780758086 · CMS profile ID 528173

Allopathic & Osteopathic Physicians / Dermatology

VALLEJO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1780758086?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PARADI MIRMIRANI, NPI 1780758086, CMS profile ID 528173. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1780758086?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). PARADI MIRMIRANI, NPI 1780758086, CMS profile ID 528173. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1780758086?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
PARADI MIRMIRANI, NPI 1780758086, CMS profile ID 528173, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1780758086?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

11 matching records · $16,185.62 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 11 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–11 of 11.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
SUN PHARMACEUTICAL INDUSTRIES INC. $700.0008/15/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1251044168 CMS
Eli Lilly and Company $800.0008/11/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1186833920 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $136.7107/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251044148 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $8,800.0006/20/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1251044150 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $129.7406/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251044152 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $52.0506/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251044154 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $25.1106/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251044156 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $214.9806/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1251044162 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $333.0706/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1251044164 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $1,143.9606/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1251044166 CMS
PFIZER INC. $3,850.0002/18/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1230485645 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,190.07 6
PY2021 $5,100.00 1
PY2022 $3,726.42 4
PY2024 $5,123.32 3
PY2025 $16,185.62 11

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $479,737.84 282
PY2024 Recipient $3,200.00 1
PY2024 Principal investigator $768,360.94 287
PY2023 Recipient $5,740.00 5
PY2023 Principal investigator $318,195.33 82
PY2022 Recipient $1,600.00 3
PY2022 Principal investigator $29,594.10 8
PY2021 Principal investigator $84,014.35 20
PY2020 Principal investigator $176,397.66 37
PY2019 Principal investigator $77,460.50 11

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

288 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $2,680.00 12/11/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671191
Principal investigator 1 Incyte Corporation $2,747.00 12/11/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671193
Principal investigator 1 Incyte Corporation $2,680.00 12/11/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671203
Principal investigator 1 Incyte Corporation $2,680.00 12/11/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671207
Principal investigator 1 Incyte Corporation $2,747.00 12/11/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671219
Principal investigator 1 Incyte Corporation $2,747.00 12/11/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671221
Principal investigator 1 Incyte Corporation $2,680.00 12/11/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671297
Principal investigator 1 Incyte Corporation $2,747.00 12/11/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671309
Principal investigator 1 Incyte Corporation $2,828.00 12/11/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671467
Principal investigator 1 Incyte Corporation $2,370.40 12/11/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671541
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $700.00 12/10/2024 Covered Recipient Teaching Hospital
Kfh - Oakland
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151790587
Principal investigator 1 Incyte Corporation $64.70 12/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671199
Principal investigator 1 Incyte Corporation $32.90 12/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671201
Principal investigator 1 Incyte Corporation $49.30 12/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671205
Principal investigator 1 Incyte Corporation $49.30 12/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671209
Principal investigator 1 Incyte Corporation $32.90 12/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671211
Principal investigator 1 Incyte Corporation $32.90 12/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671213
Principal investigator 1 Incyte Corporation $32.90 12/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671215
Principal investigator 1 Incyte Corporation $64.70 12/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671217
Principal investigator 1 Incyte Corporation $49.30 12/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671289
Principal investigator 1 Incyte Corporation $49.30 12/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671291
Principal investigator 1 Incyte Corporation $68.70 12/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671493
Principal investigator 1 Incyte Corporation $135.40 12/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671495
Principal investigator 1 Incyte Corporation $49.40 12/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671497
Principal investigator 1 Incyte Corporation $54.80 12/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671499
Principal investigator 1 Incyte Corporation $59.10 12/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671501
Principal investigator 1 Incyte Corporation $14.80 12/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671503
Principal investigator 1 Incyte Corporation $62.30 12/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671505
Principal investigator 1 Incyte Corporation $24.30 12/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671507
Principal investigator 1 Incyte Corporation $98.70 12/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671509
Principal investigator 1 Incyte Corporation $270.80 12/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671511
Principal investigator 1 Incyte Corporation $114.50 12/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671513
Principal investigator 1 Incyte Corporation $12.40 12/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671539
Principal investigator 1 Incyte Corporation $1.20 12/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671557
Principal investigator 1 Incyte Corporation $1,500.00 11/18/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671195
Principal investigator 1 Incyte Corporation $1,500.00 11/18/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671223
Principal investigator 1 Incyte Corporation $1,200.00 11/18/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671261
Principal investigator 1 Incyte Corporation $1,200.00 11/18/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671263
Principal investigator 1 Incyte Corporation $900.00 11/18/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671471
Principal investigator 1 Incyte Corporation $1,120.00 11/18/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671473
Principal investigator 1 Incyte Corporation $3,000.00 11/18/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671475
Principal investigator 1 Incyte Corporation $1,026.00 11/18/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671477
Principal investigator 1 Incyte Corporation $300.00 11/18/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671479
Principal investigator 1 PFIZER INC. $6,300.00 11/07/2024 Covered Recipient Teaching Hospital
KFH - ANTIOCH
A PHASE 3 OPENLABEL MULTICENTER LONGTERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF06651600 IN ADULT AND ADOLESCENT PARTICIPANTS WITH ALOPECIA AREATA No dispute reported 06/30/2026 1130984162
Principal investigator 1 Incyte Corporation $2,780.00 11/06/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671231
Principal investigator 1 Incyte Corporation $2,780.00 11/06/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671233
Principal investigator 1 Incyte Corporation $2,780.00 11/06/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671235
Principal investigator 1 Incyte Corporation $2,780.00 11/06/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671313
Principal investigator 1 Incyte Corporation $710.30 11/06/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671459
Principal investigator 1 Incyte Corporation $2,747.00 11/06/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671461
Principal investigator 1 Incyte Corporation $3,150.00 11/06/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671519
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $750.00 10/17/2024 Covered Recipient Teaching Hospital
Kfh - Oakland
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151790581
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $18,660.00 10/17/2024 Covered Recipient Teaching Hospital
Kfh - Oakland
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151790583
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $700.00 10/17/2024 Covered Recipient Teaching Hospital
Kfh - Oakland
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151790585
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $600.00 10/16/2024 Covered Recipient Teaching Hospital
Kfh - Oakland
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151790577
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $18,569.70 10/16/2024 Covered Recipient Teaching Hospital
Kfh - Oakland
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151790579
Principal investigator 1 Incyte Corporation $2,680.00 10/11/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671187
Principal investigator 1 Incyte Corporation $3,411.00 10/11/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671189
Principal investigator 1 Incyte Corporation $3,386.00 10/11/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671225
Principal investigator 1 Incyte Corporation $2,680.00 10/11/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671227
Principal investigator 1 Incyte Corporation $3,411.00 10/11/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671229
Principal investigator 1 Incyte Corporation $3,386.00 10/11/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671265
Principal investigator 1 Incyte Corporation $2,680.00 10/11/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671311
Principal investigator 1 Incyte Corporation $3,150.00 10/11/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671463
Principal investigator 1 Incyte Corporation $23.60 10/11/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671465
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $150.00 10/11/2024 Covered Recipient Teaching Hospital
Kfh - Oakland
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151790573
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $22,019.40 10/11/2024 Covered Recipient Teaching Hospital
Kfh - Oakland
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151790575
Principal investigator 1 Incyte Corporation $41.10 10/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671197
Principal investigator 1 Incyte Corporation $41.10 10/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671283
Principal investigator 1 Incyte Corporation $41.10 10/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671285
Principal investigator 1 Incyte Corporation $41.10 10/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671287
Principal investigator 1 Incyte Corporation $175.00 10/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671469
Principal investigator 1 Incyte Corporation $123.40 10/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671481
Principal investigator 1 Incyte Corporation $242.70 10/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671483
Principal investigator 1 Incyte Corporation $38.90 10/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671485
Principal investigator 1 Incyte Corporation $7.80 10/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671487
Principal investigator 1 Incyte Corporation $270.80 10/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671489
Principal investigator 1 Incyte Corporation $124.50 10/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671491
Principal investigator 1 Incyte Corporation $183.20 10/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671527
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $300.00 10/02/2024 Covered Recipient Teaching Hospital
Kfh - Oakland
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151790571
Principal investigator 1 Incyte Corporation $2,747.00 09/18/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671173
Principal investigator 1 Incyte Corporation $2,747.00 09/18/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671175
Principal investigator 1 Incyte Corporation $4,090.40 09/18/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671447
Principal investigator 1 Incyte Corporation $2,780.00 09/18/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671453
Principal investigator 1 Incyte Corporation $3,150.00 09/18/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671525
Principal investigator 1 PFIZER INC. $14,119.00 09/12/2024 Covered Recipient Teaching Hospital
KFH - ANTIOCH
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1131021593
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $700.00 09/05/2024 Covered Recipient Teaching Hospital
Kfh - Oakland
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151790569
Principal investigator 1 Incyte Corporation $62.27 09/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671323
Principal investigator 1 Incyte Corporation $135.40 09/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671531
Principal investigator 1 Incyte Corporation $2,828.00 08/14/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671167
Principal investigator 1 Incyte Corporation $2,680.00 08/14/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671169
Principal investigator 1 Incyte Corporation $3,411.00 08/14/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671171
Principal investigator 1 Incyte Corporation $3,411.00 08/14/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671179
Principal investigator 1 Incyte Corporation $2,828.00 08/14/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671181
Principal investigator 1 Incyte Corporation $2,680.00 08/14/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671183
Principal investigator 1 Incyte Corporation $2,780.00 08/14/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671455
Principal investigator 1 Incyte Corporation $372.30 08/14/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671457
Principal investigator 1 Incyte Corporation $2,747.00 08/14/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671555
Principal investigator 1 Incyte Corporation $3,386.00 08/14/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671561
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $150.00 08/07/2024 Covered Recipient Teaching Hospital
Kfh - Oakland
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151790567
Principal investigator 1 Incyte Corporation $41.10 08/01/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671165
Principal investigator 1 Incyte Corporation $41.10 08/01/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671185
Principal investigator 1 Incyte Corporation $41.10 08/01/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671303
Principal investigator 1 Incyte Corporation $41.10 08/01/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671305
Principal investigator 1 Incyte Corporation $4.65 08/01/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671423
Principal investigator 1 Incyte Corporation $91.60 08/01/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671425
Principal investigator 1 Incyte Corporation $129.44 08/01/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671427
Principal investigator 1 Incyte Corporation $123.40 08/01/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671429
Principal investigator 1 Incyte Corporation $270.80 08/01/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671431
Principal investigator 1 Incyte Corporation $34.02 08/01/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671547
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $27,354.60 07/23/2024 Covered Recipient Teaching Hospital
Kfh - Oakland
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151790563
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $24,739.20 07/23/2024 Covered Recipient Teaching Hospital
Kfh - Oakland
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151790565
Principal investigator 1 Incyte Corporation $1,500.00 07/17/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671433
Principal investigator 1 Incyte Corporation $750.00 07/17/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671435
Principal investigator 1 Incyte Corporation $300.00 07/17/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671439
Principal investigator 1 Incyte Corporation $1,026.00 07/17/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671443
Principal investigator 1 Incyte Corporation $140.00 07/17/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671445
Principal investigator 1 Incyte Corporation $100.00 07/17/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671451
Principal investigator 1 Incyte Corporation $175.00 07/17/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671543
Principal investigator 1 Incyte Corporation $4,000.00 07/17/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671553
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $700.00 07/15/2024 Covered Recipient Teaching Hospital
Kfh - Oakland
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151790561
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $7,300.00 07/11/2024 Covered Recipient Teaching Hospital
Kfh - Oakland
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151790557
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,800.00 07/11/2024 Covered Recipient Teaching Hospital
Kfh - Oakland
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151790559
Principal investigator 1 Incyte Corporation $2,780.00 07/10/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671177
Principal investigator 1 Incyte Corporation $2,780.00 07/10/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671301
Principal investigator 1 Incyte Corporation $2,828.00 07/10/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671317
Principal investigator 1 Incyte Corporation $2,747.00 07/10/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671437
Principal investigator 1 Incyte Corporation $3,411.00 07/10/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671441
Principal investigator 1 Incyte Corporation $679.10 07/10/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671523
Principal investigator 1 Incyte Corporation $3,386.00 07/10/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671551
Principal investigator 1 Incyte Corporation $21.87 07/05/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671421
Principal investigator 1 Incyte Corporation $32.88 07/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671253
Principal investigator 1 Incyte Corporation $32.88 07/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671255
Principal investigator 1 Incyte Corporation $32.88 07/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671257
Principal investigator 1 Incyte Corporation $32.88 07/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671259
Principal investigator 1 Incyte Corporation $19.44 07/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671449
Principal investigator 1 PFIZER INC. $105.00 06/25/2024 Covered Recipient Teaching Hospital
KFH - ANTIOCH
A PHASE 3 OPENLABEL MULTICENTER LONGTERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF06651600 IN ADULT AND ADOLESCENT PARTICIPANTS WITH ALOPECIA AREATA No dispute reported 06/30/2026 1131069423
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,000.00 06/20/2024 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata No dispute reported 06/30/2026 1151790597
Principal investigator 1 Incyte Corporation $1,875.00 06/14/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671377
Principal investigator 1 Incyte Corporation $11,250.00 06/14/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671389
Principal investigator 1 Incyte Corporation $2,000.00 06/14/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671391
Principal investigator 1 Incyte Corporation $4,000.00 06/14/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671395
Principal investigator 1 Incyte Corporation $2,500.00 06/14/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671559
Principal investigator 1 Incyte Corporation $2,747.00 06/07/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671381
Principal investigator 1 Incyte Corporation $3,150.00 06/07/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671383
Principal investigator 1 Incyte Corporation $1,967.30 06/07/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671417
Principal investigator 1 Incyte Corporation $2,780.00 06/07/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671535
Principal investigator 1 Incyte Corporation $137.40 06/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671407
Principal investigator 1 Incyte Corporation $270.80 06/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671409
Principal investigator 1 Incyte Corporation $62.27 06/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671411
Principal investigator 1 Incyte Corporation $59.13 06/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671413
Principal investigator 1 Incyte Corporation $48.54 06/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671549
Principal investigator 1 Amgen Inc. $6,056.23 05/28/2024 Non-covered Recipient Entity
KAISER PERMANENTE MEDICAL CENTER - SAN FRANCISCO
ASCEND P3 AD Extension No dispute reported 06/30/2026 1096309271
Principal investigator 1 Amgen Inc. $9,674.17 05/28/2024 Covered Recipient Teaching Hospital
KFH - MORENO VALLEY
ASCEND P3 AD Extension No dispute reported 06/30/2026 1096309541
Principal investigator 1 Incyte Corporation $2,747.00 05/03/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671161
Principal investigator 1 Incyte Corporation $2,747.00 05/03/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671163
Principal investigator 1 Incyte Corporation $2,680.00 05/03/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671379
Principal investigator 1 Incyte Corporation $1,316.60 05/03/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671515
Principal investigator 1 Incyte Corporation $2,780.00 05/03/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671565
Recipient PFIZER INC. $3,200.00 05/03/2024 Covered Recipient Physician RITLECITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1130902140
Principal investigator 1 PFIZER INC. $925.00 05/03/2024 Covered Recipient Teaching Hospital
KFH - ANTIOCH
A PHASE 3 OPENLABEL MULTICENTER LONGTERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF06651600 IN ADULT AND ADOLESCENT PARTICIPANTS WITH ALOPECIA AREATA No dispute reported 06/30/2026 1131081501
Principal investigator 1 Incyte Corporation $135.40 05/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671321
Principal investigator 1 Amgen Inc. $20,621.00 04/20/2024 Covered Recipient Teaching Hospital
KFH - MORENO VALLEY
SHUTTLE P3 AD Adult Combo TCS No dispute reported 06/30/2026 1096315927
Principal investigator 1 Amgen Inc. $63,529.00 04/20/2024 Covered Recipient Teaching Hospital
KFH - SAN FRANCISCO
SHUTTLE P3 AD Adult Combo TCS No dispute reported 06/30/2026 1096315931
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $22,605.57 04/17/2024 Covered Recipient Teaching Hospital
Kfh - Oakland
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151790553
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $20,480.40 04/17/2024 Covered Recipient Teaching Hospital
Kfh - Oakland
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151790555
Principal investigator 1 Incyte Corporation $750.00 04/12/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671373
Principal investigator 1 Incyte Corporation $2,500.00 04/12/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671385
Principal investigator 1 Incyte Corporation $10,500.00 04/12/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671387
Principal investigator 1 Incyte Corporation $4,000.00 04/12/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671393
Principal investigator 1 Incyte Corporation $1,875.00 04/12/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671415
Principal investigator 1 Incyte Corporation $2,780.00 04/05/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671325
Principal investigator 1 Incyte Corporation $1,909.00 04/05/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671419
Principal investigator 1 Incyte Corporation $3,150.00 04/05/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671563
Principal investigator 1 Incyte Corporation $68.90 04/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671397
Principal investigator 1 Incyte Corporation $1.24 04/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671399
Principal investigator 1 Incyte Corporation $64.72 04/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671401
Principal investigator 1 Incyte Corporation $98.72 04/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671403
Principal investigator 1 Incyte Corporation $37.66 04/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671405
Principal investigator 1 Incyte Corporation $106.00 04/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671533
Principal investigator 1 Incyte Corporation $26.50 04/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671545
Principal investigator 1 Incyte Corporation $32.28 04/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671567
Principal investigator 1 Eli Lilly and Company $59,496.80 03/26/2024 Covered Recipient Teaching Hospital
KFH - SANTA CLARA
A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA No dispute reported 06/30/2026 1137350895
Principal investigator 1 Incyte Corporation $3,386.00 03/13/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671083
Principal investigator 1 Incyte Corporation $3,386.00 03/13/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671119
Principal investigator 1 Incyte Corporation $2,680.00 03/13/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671331
Principal investigator 1 Incyte Corporation $3,411.00 03/13/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671333
Principal investigator 1 Incyte Corporation $1,508.90 03/13/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671375
Principal investigator 1 Incyte Corporation $2,747.00 03/13/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671529
Principal investigator 1 Incyte Corporation $14.58 03/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671085
Principal investigator 1 Incyte Corporation $41.10 03/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671115
Principal investigator 1 Incyte Corporation $41.10 03/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671123
Principal investigator 1 Incyte Corporation $41.10 03/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671131
Principal investigator 1 Incyte Corporation $49.32 03/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671237
Principal investigator 1 Incyte Corporation $49.32 03/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671239
Principal investigator 1 Incyte Corporation $49.32 03/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671241
Principal investigator 1 Incyte Corporation $49.32 03/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671243
Principal investigator 1 Incyte Corporation $24.66 03/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671245
Principal investigator 1 Incyte Corporation $24.66 03/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671247
Principal investigator 1 Incyte Corporation $24.66 03/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671249
Principal investigator 1 Incyte Corporation $24.66 03/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671251
Principal investigator 1 Incyte Corporation $14.58 03/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671293
Principal investigator 1 Incyte Corporation $41.10 03/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671299
Principal investigator 1 Incyte Corporation $113.26 03/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671315
Principal investigator 1 Incyte Corporation $4.96 03/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671335
Principal investigator 1 Incyte Corporation $74.04 03/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671339
Principal investigator 1 Incyte Corporation $114.50 03/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671341
Principal investigator 1 Incyte Corporation $59.13 03/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671353
Principal investigator 1 Incyte Corporation $34.02 03/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671357
Principal investigator 1 Incyte Corporation $148.08 03/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671361
Principal investigator 1 Incyte Corporation $62.27 03/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671363
Principal investigator 1 Incyte Corporation $135.40 03/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671367
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $18,843.50 02/22/2024 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata No dispute reported 06/30/2026 1151790593
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $28,796.70 02/22/2024 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata No dispute reported 06/30/2026 1151790595
Principal investigator 1 PFIZER INC. $495.00 02/11/2024 Non-covered Recipient Entity
KAISER PERMANENTE
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1131093593
Principal investigator 1 PFIZER INC. $150.00 02/11/2024 Non-covered Recipient Entity
KAISER PERMANENTE
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1131093903
Principal investigator 1 Incyte Corporation $2,780.00 02/07/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671319
Principal investigator 1 Incyte Corporation $2,791.90 02/07/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671327
Principal investigator 1 PFIZER INC. $495.00 02/07/2024 Non-covered Recipient Entity
KAISER PERMANENTE
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1131093598
Principal investigator 1 PFIZER INC. $150.00 02/07/2024 Non-covered Recipient Entity
KAISER PERMANENTE
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1131093910
Principal investigator 1 PFIZER INC. $3,000.00 02/07/2024 Non-covered Recipient Entity
KAISER PERMANENTE
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1131093981
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $34,282.80 02/07/2024 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata No dispute reported 06/30/2026 1151790591
Principal investigator 1 Incyte Corporation $2.43 02/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671345
Principal investigator 1 Incyte Corporation $0.31 02/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671349
Principal investigator 1 Incyte Corporation $8.99 02/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671351
Principal investigator 1 Incyte Corporation $16.18 02/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671359
Principal investigator 1 Incyte Corporation $171.75 02/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671365
Principal investigator 1 Incyte Corporation $226.52 02/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671371
Principal investigator 1 Incyte Corporation $123.40 02/02/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671521
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $15,980.00 02/02/2024 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata No dispute reported 06/30/2026 1151790589
Principal investigator 1 PFIZER INC. $1,241.50 01/25/2024 Covered Recipient Teaching Hospital
KFH - ANTIOCH
A PHASE 3 OPENLABEL MULTICENTER LONGTERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF06651600 IN ADULT AND ADOLESCENT PARTICIPANTS WITH ALOPECIA AREATA No dispute reported 06/30/2026 1131108720
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $24,652.80 01/25/2024 Covered Recipient Teaching Hospital
Kfh - Oakland
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151790551
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $23,688.99 01/24/2024 Covered Recipient Teaching Hospital
Kfh - Oakland
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151790549
Principal investigator 1 Amgen Inc. $2,307.77 01/19/2024 Covered Recipient Teaching Hospital
KFH - SAN FRANCISCO
SHUTTLE P3 AD Adult Combo TCS No dispute reported 06/30/2026 1096315933
Principal investigator 1 Amgen Inc. $2,291.12 01/08/2024 Covered Recipient Teaching Hospital
KFH - MORENO VALLEY
SHUTTLE P3 AD Adult Combo TCS No dispute reported 06/30/2026 1096315929
Principal investigator 1 Incyte Corporation $3,047.40 01/08/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671329
Principal investigator 1 Incyte Corporation $41.10 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671079
Principal investigator 1 Incyte Corporation $41.10 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671081
Principal investigator 1 Incyte Corporation $7.29 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671087
Principal investigator 1 Incyte Corporation $1.55 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671089
Principal investigator 1 Incyte Corporation $0.62 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671091
Principal investigator 1 Incyte Corporation $54.76 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671093
Principal investigator 1 Incyte Corporation $48.60 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671095
Principal investigator 1 Incyte Corporation $45.80 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671097
Principal investigator 1 Incyte Corporation $48.54 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671099
Principal investigator 1 Incyte Corporation $49.32 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671101
Principal investigator 1 Incyte Corporation $24.30 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671103
Principal investigator 1 Incyte Corporation $57.25 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671105
Principal investigator 1 Incyte Corporation $62.27 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671107
Principal investigator 1 Incyte Corporation $97.08 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671109
Principal investigator 1 Incyte Corporation $135.40 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671111
Principal investigator 1 Incyte Corporation $172.76 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671113
Principal investigator 1 Incyte Corporation $59.13 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671117
Principal investigator 1 Incyte Corporation $7.29 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671121
Principal investigator 1 Incyte Corporation $41.10 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671125
Principal investigator 1 Incyte Corporation $41.10 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671127
Principal investigator 1 Incyte Corporation $24.30 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671129
Principal investigator 1 Incyte Corporation $48.60 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671133
Principal investigator 1 Incyte Corporation $45.80 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671135
Principal investigator 1 Incyte Corporation $48.54 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671137
Principal investigator 1 Incyte Corporation $54.76 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671139
Principal investigator 1 Incyte Corporation $57.25 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671141
Principal investigator 1 Incyte Corporation $62.27 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671143
Principal investigator 1 Incyte Corporation $59.13 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671145
Principal investigator 1 Incyte Corporation $135.40 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671147
Principal investigator 1 Incyte Corporation $172.76 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671149
Principal investigator 1 Incyte Corporation $97.08 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671151
Principal investigator 1 Incyte Corporation $0.62 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671153
Principal investigator 1 Incyte Corporation $49.32 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671155
Principal investigator 1 Incyte Corporation $49.32 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671157
Principal investigator 1 Incyte Corporation $24.30 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671159
Principal investigator 1 Incyte Corporation $57.54 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671267
Principal investigator 1 Incyte Corporation $57.54 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671269
Principal investigator 1 Incyte Corporation $57.54 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671271
Principal investigator 1 Incyte Corporation $57.54 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671273
Principal investigator 1 Incyte Corporation $57.54 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671275
Principal investigator 1 Incyte Corporation $57.54 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671277
Principal investigator 1 Incyte Corporation $57.54 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671279
Principal investigator 1 Incyte Corporation $57.54 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671281
Principal investigator 1 Incyte Corporation $1.55 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671295
Principal investigator 1 Incyte Corporation $49.32 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671307
Principal investigator 1 Incyte Corporation $2.79 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671337
Principal investigator 1 Incyte Corporation $64.72 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671343
Principal investigator 1 Incyte Corporation $148.08 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671347
Principal investigator 1 Incyte Corporation $12.15 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671355
Principal investigator 1 Incyte Corporation $123.40 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671369
Principal investigator 1 Incyte Corporation $3.10 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671517
Principal investigator 1 Incyte Corporation $1.86 01/04/2024 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134671537